Zantac Cancer Trials Consolidated In Federal Court
A federal judge has cleared the way for Zantac cancer plaintiffs to move forward and pursue their claims against Sanofi, the maker of Zantac, in Federal Court
Sunday, January 10, 2021 - Judge Robin Rosenberg has decided that cases against Sanofi about Zantac cancer are to be organized federally, preempting individual lawsuits filed state by state. Lawyers told TodayWestLaw.com (TWL), "The court's ruling today on the brand manufacturers' motion to dismiss provides further clarity and a road map for plaintiffs to move forward with individual and class claims against defendants involved in the manufacture of Zantac, a cancer-causing drug that the FDA directed be withdrawn from the market in April 2020. There are currently more than 500 Zantac Cancer lawsuits in multidistrict litigation (MDL) before the judge. The judge's ruling upholds a motion by Sanofi, GlaxoSmithKline, Pfizer Inc, and Boehringer Ingelheim to "dismiss all state economic damages claims."
The judge's decision may help juries better understand the science governing the development of NDMA, a carcinogen, in Zantac antacid tablets. Judge Rosenberg could decide to hold hearings to get to the bottom of the facts about the escalation of NDMA in Zantac and filter out inflammatory rhetoric and exaggerations that might inflame juries. The judge's decision clears the way for interviews of experts and scientists to determine what went wrong with Zantac medicine. NDMA in Zantac may increase because of being stored at high temperatures, the chemical reacting to stomach nitrates, or possibly at the source of the drug's manufacturer in China or India. NDMA was used by scientists to induce cancer tumors in laboratory test animals.
Interviews of experts that may be conducted via Daubert hearings have not as of yet been discussed or scheduled and could push the start of Zantac Cancer trials back one year or more. Sanofi is accused of "negligence, violation of state consumer protection laws, design defects, and other charges," according to TWL.
Zantac is the all-time best-selling heartburn and acid reflux medicine, earning Sanofi millions of dollars in revenue every year. Over 15 million Americans were estimated to take the drug regularly until April 1, 2020, when Zantac and all other brands of ranitidine were recalled and the further sale banned by the Food and Drug Administration (FDA). Online drug testing pharmacy Valisure tested Zantac and found levels of NDMA, a known carcinogen, orders of magnitude greater than FDA permissible levels. Valisure reportedly found over three million NGS of NDMA in Zantac, far exceeding the 96 ng/tabled FDA threshold for safety. Individuals that were suffering from cancer or the estates of those that have died that used Zantac regularly for many years have hired Zantac Cancer Lawyers, and have filed lawsuits claiming Zantac caused their disease and that Sanofi knew and had an obligation to warn them. The Department of Justice is also concerned that Sanofi may have lied to government regulators about their knowledge of the Zantac being contaminated with the deadly carcinogen and has opened an investigation against the company.
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
- Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
- Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
- A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
- Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
- Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
- Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
- Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
- The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
- Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
- Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
- Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
- Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
- Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
- Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
- Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.